Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Jetstar to Charge for Overhead Cabin Bags From February 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
HOPKINTON, Mass., March 09, 2018 -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Martin J. Driscoll, chairman, president, and chief executive officer of Spring Bank, will present at the upcoming Cowen and Company 38th Annual Health Care Conference, taking place March 12-14 at the Boston Marriott Copley Place hotel in Boston, Massachusetts.
| Cowen and Company 38th Annual Health Care Conference | ||
| Date: | Wednesday, March 14 | |
| Time: | 9:20am Eastern Time | |
About Spring Bank
Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that the company designs to selectively target and modulate the activity of specific proteins implicated in various disease states. The company is developing its most advanced SMNH product candidate, inarigivir, for the treatment of viral diseases, including hepatitis B virus (HBV) and other SMNH product candidates, including SB 11285, the company’s lead immunotherapeutic agent for the treatment of selected cancers through the activation of the STimulator of INterferon Genes, or STING, pathway.
Contacts
For investor inquires:
Spring Bank Pharmaceuticals, Inc.
Jonathan Freve
Chief Financial Officer
(508) 473-5993
LifeSci Advisors, LLC
Andrew McDonald
(646) 597-6987
[email protected]
Media contact:
Josephine Belluardo, Ph.D.
LifeSci Public Relations
(646) 751-4361
[email protected]
